Net Loss per Common Share

6 Months Ended

Sep. 30, 2023

Net Loss per Common Share [Abstract]

Note 14—Net Loss per Common Share

Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period.

For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss.

As of September 30, 2023 and 2022, potentially dilutive securities were as follows:

	September 30, 2023		September 30, 2022
Stock options and performance stock options		148,753,920		154,836,057
Restricted stock units and performance stock units (non-vested)		20,073,411		25,214,766
March 2020 CVARs⁽¹⁾		28,753,677		32,011,996
November 2021 CVARs (non-vested)		2,506,499		4,060,128
Restricted common stock (non-vested)		487,005		772,018
Earn-Out Shares (non-vested)		3,080,387		3,080,387
Private Placement Warrants		—		10,214,365
Public Warrants		—		20,475,875
Other stock based awards and instruments issued		5,611,820		6,209,162

⁽¹⁾	Refer to Note 9, “Share-Based Compensation” for details regarding settlement of CVARs.